Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

OBJECTIVE: This phase 3 study aimed to test equivalence in efficacy and safety for QL1101, a bevacizumab analogue in Chinese patients with untreated locally advanced non-squamous non-small cell lung cancer (NSCLC). METHODS: Eligible patients were randomly assigned 1:1 to receive carboplatin and pacl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Tianqing, Lu, Jun, Bi, Minghong, Zhang, Helong, Zhuang, Wu, Yu, Yan, Shi, Jianhua, Chen, Zhendong, Zhang, Xiaochun, Guo, Qisen, Liu, Quan, Wu, Huijuan, Fang, Jian, Hu, Yi, Wang, Xiuwen, Han, Cuicui, Li, Kai, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330542/
https://www.ncbi.nlm.nih.gov/pubmed/33710815
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330542/
https://www.ncbi.nlm.nih.gov/pubmed/33710815
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0212

Ejemplares similares